KV Pharmaceutical Cleared To Resume Some Drug Shipments, But Cash Crisis Looms
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA gives go-ahead for the beleaguered company to ship two potassium chloride formulations following a satisfactory GMP inspection in August.
You may also be interested in...
KV Emerging From Bankruptcy As Makena Sales Pick Up Steam
KV clears major hurdle as court okays its chapter 11 reorganization plan, which provides for payment of $23.4 million owed under 2010 Department of Justice settlement and $231.4 million for senior notes; firm’s future remains tied to Makena.
KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval
Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.
KV's Gestiva Reemerges With New Name, Makena, And A Long-Sought FDA Approval
Approval of the pre-term birth prevention therapy could pull KV Pharmaceutical back from the brink.